Inspira Technologies Expands Patent Portfolio with Latest Approval
Inspira Technologies Secures New U.S. Patent Approval
Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, NASDAQ: IINNW) has achieved a significant milestone by securing a second U.S. patent approval for its orbiting blood oxygenation delivery system known as the VORTX™. This innovative technology is critical to the functionality of the INSPIRA™ ART device.
Groundbreaking Technology for ICU Patients
The VORTX™ system stands out for its potential to oxygenate blood without relying on traditional fiber membranes. This advancement aims to assist the approximately 20 million intensive care unit patients dealing with respiratory failure annually, many of whom depend on mechanical ventilators in a competitive $19 billion market.
The Advancements of the VORTX™ System
This new patent approval brings the total claims related to the INSPIRA™ ART device to 32, demonstrating the device's transformative potential in modern medicine. The VORTX™ technology is designed to minimize blood cell damage, thus revolutionizing blood oxygenation methods that currently lead to harmful side effects due to turbulent blood flow through fiber materials. By bypassing fiber membranes, the VORTX™ aims to avoid complications such as hemolysis and activated immune responses.
Insights from Company Leadership
Dagi Ben-Noon, the CEO of Inspira Technologies, expressed enthusiasm over the recent patent approval, stating that it marks another critical step in their journey to advance blood oxygenation technologies. He emphasized the company’s vision of maintaining patient comfort and safety while providing an innovative alternative to traditional ventilator systems.
Impact and Market Potential
The INSPIRA™ ART technology is poised to change the landscape for patients suffering from respiratory issues. Unlike mechanical ventilators, the INSPIRA™ ART promotes stable oxygen levels, allowing many patients to remain conscious throughout the treatment process. This shift highlights the device’s role in transforming the way respiratory care is delivered in intensive settings.
About Inspira Technologies
Inspira Technologies is a pioneering player in the medical technology sector focused on respiratory treatments. Their flagship technology, the INSPIRA™ ART, is equipped with advanced blood monitoring systems that ensure patient safety while reducing the need for invasive procedures traditionally associated with mechanical ventilation.
Certifications and Future Developments
The Company’s INSPIRA™ ART100 system has obtained FDA clearance for use in cardiopulmonary bypass procedures and has received the AMAR certification for both ECMO and cardiopulmonary bypass applications in specific markets. Additionally, Inspira is in the process of designing other innovative devices, such as the INSPIRA™ Cardi-ART portable module and the HYLA™ blood sensor, which are aimed at enhancing patient care.
Frequently Asked Questions
What is the primary focus of Inspira Technologies?
Inspira Technologies specializes in developing advanced medical technologies aimed at improving respiratory treatment methods, particularly for ICU patients.
What innovations does the VORTX™ system introduce?
The VORTX™ system introduces a method of oxygenating blood without fiber membranes, aiming to reduce damage to blood cells and improve patient outcomes.
How many U.S. patents does Inspira Technologies have for its device?
Inspira Technologies has secured a total of 32 novel claims related to its core INSPIRA™ ART technology through recent patent approvals.
What impact does Inspira's technology have on ICU patient treatment?
The INSPIRA™ ART allows patients in the ICU to maintain stable oxygen levels while remaining awake, potentially reducing the need for invasive mechanical ventilation.
What certifications has the INSPIRA™ ART system achieved?
The INSPIRA™ ART100 system has received FDA 510(k) clearance and the AMAR certification for its use in cardiopulmonary bypass procedures.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.